adMare Bioinnovations Tx Accelerator
Accelerator
Description:
The Tx Accelerator focuses on early-stage biotherapeutic ventures with the potential for significant market impact. This is a service for equity model with up to $250K provided in integrated services per venture with 5% common equity due only if the company raises more than $3M (at a valuation of at least $4M). Integrated services include: – Scientific and regulatory guidance for pre-clinical and clinical studies;
– Coaching and expertise in business development and IP strategy;
– Access to advanced personalized training and team building;
– Access to the adMare Community digital platform, C-suite executives, industry partners, and investors;
– Direct financial support for ventures to scale-up and complete growth-related milestones;
– Access to state-of-the-art wet laboratory facilities and office space (adMare labs and vivarium in QC and BC, MaRS facility in ON).
Comments on Funding:
Rolling deadline
Eligibility:
Applicants must:
1. be early-stage biotherapeutic ventures with the potential for significant market impact;
2. be ventures working in the following areas will be considered high-priority:
a) Therapeutics: broad range of disease indications (e.g., immunology, oncology, neurology, metabolomics) and categories (e.g., small molecules, biologics, cell and gene therapies);
b) Artificial intelligence/machine learning platforms: supporting drug discovery or digital therapeutics;
c) Enabling platforms: novel drug screen, discovery, and delivery platforms that can result in a novel drug-related IP.
3. be ventures incorporated in Canada with ambitious growth plans, have at least 1 employee, have proprietary IP, and have raised pre-seed funding.
Application Steps:
For details about this program, contact
adMare.
Documentation Needed:
No specific documentation has been identified.
Other Things to Note:
About the author
Maurice
